Key Points
Growing evidence suggests tirzepatide may be extremely effective for weight loss.Patients taking tirzepatide lost more weight than with semaglutide or Ozempic.The drug is pending FDA approval for weight loss, but available as a diabetes treatment...
Patients taking a once-weekly injection of tirzepatide, currently available to diabetes patients under the brand name Mounjaro, lost more than 24% of their body weight, on average, by the end of the 84-week trial, according to new research..
It's also promising news for manufacturer Eli Lilly, which is developing a new brand name version of tirzepatide for weight loss, which awaits FDA approval...
One 2021 study on the effects of tirzepatide versus semaglutide on patients with type 2 diabetes found that tirzepatide led to more weight loss..
Manufacturer Eli Lilly's most recent announcement anticipates an update on the FDA approval process for tirzepatide as a weight loss treatment in late 2023...
You might be interested in
The next game-changing weight loss drug just moved closer to FDA approval
27, Apr, 23In a new study, patients on tirzepatide (Mounjaro) lost nearly 16% of their body weight in 16 months.
Mounjaro costs $1000 a month without coupon; user fears regaining weight
24, May, 23Mounjaro costs more than $1,000 a month without a coupon, and most insurance plans don't cover weigh-loss drugs. Some patients are worried about how to afford it.
Mounjaro: Weight loss drug suppresses appetite, awaits FDA approval
17, Mar, 23Tirzepatide, sold as Mounjaro, is a diabetes medication being considered for use to treat obesity, like the related drug semaglutide.